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Introduction 27
The current paradigm of drug therapy follows a "trial-and-error" approach where patients are 28 prescribed a drug at a standardized dose with the expectation that alternative therapies or 29 doses will be given during a return clinical visit(s). 1 Not surprisingly, this is inefficient and 30 potentially hazardous for patients who require urgent care or are susceptible to adverse events, 31 which may result in prolonged suffering and fatalities. 2 A better understanding of the 32 modulators of drug response will improve and hopefully replace our current trial-and-error 33 approach of drug therapy with more precise methods that are based on scientific knowledge. 3 
34
To date, more than 1,100 genetic loci have been correlated with drug response 35 phenotypes (The Pharmacogenomics Knowledgebase (PharmGKB): www.pharmgkb.org) but 36 only a small fraction of these genomic findings have been implemented into clinical practice. 37
In 2009, PharmGKB partnered with the Pharmacognomics Research Network (PGRN) to 38 establish the Clinical Pharmacogenetics Implementation Consortium (CPIC)). 4, 5, 6 The goal of 39 CPIC is to provide specific guidelines that instruct clinicians on how to use or interpret a 40 patient's genetic test results to determine the optimal drug and dosage to each patient. As of 41
June 2017, there are 36 drug-gene pairs with CPIC guidelines published, although there are 42 commonly used drug for the prevention of thrombosis. 7 Warfarin is known to have a narrow 48 therapeutic index and wide effect variances among patients. For example, a conventional 49 dose of warfarin may not be an effective anticoagulant in some patients or induce adverse 50 events (e.g. excessive bleeding) in others. 8 Thus, it is often difficult to achieve and maintain a 51 targeted effect by administering conventional doses. Recent advancement in 52 pharmacogenomics helped to facilitate genetic tests of two genes that can be used to predict a 53 patients' sensitivity to the drug prior to administration. Specifically, the therapeutic dosage of 54 warfarin may be calculated based on one's genotypes at these loci, which has resulted in a 55 significant improvement in drug safety. 8,9 56 Despite the successful translation of a small fraction of pharmacogenomics findings 57 into clinical practice, the rate of clinical implementation has been slow. 6 One explanation is 58 that the majority of pharmacogenomics loci are correlated with drug response but do not 59 represent the actual, causal variants themselves. 10, 11, 12 We hypothesize that the majority of 60 known pharmacogenomics loci are genetic markers that tag causal variants, which have yet to 61 be identified and are likely to be in linkage disequilibrium (LD) with the associated markers. 62
The use of associated variants instead of the causal variants in clinical tests is limiting in that 63 it may not reliably predict drug response. 13 64
The primary objective of this study is to identify potentially causal variants in well-65 established pharmacogenomics-associated genes, which may account for the reported 66 association signals. Specifically, we used whole genome sequencing data from the 1000 67
Genomes Project 14,15 to derive all genetic variations identified within the 160 unique CPIC 68 and VIP pharmacogenomics genes. Next, we tested the LD with known pharmacogenomic 69 variants, and determined the predicted function of these LD variants using annotation 70 databases and clinical outcome databases. Our results include a catalog of potentially 71 functional variants that are in LD with well-established pharmacogenomics variants and 72 could represent the causative mutations within these loci. 73
Results 74

Selection of pharmacogenomics loci and annotation of variants 75
We selected 127 CPIC genes and 64 VIP genes (total of 160 unique loci) from PharmGKB, 76 which we deemed as "well-established" pharmacogenomics loci (Supplemental data 1). 77
Next, we identified 887,980 variants within these loci using next generation sequencing data 78 from the 1000 Genomes Project Phase I, of which 69,319 were variants with minor allele 79 frequencies > 1% (Supplemental data 2). Annotation analysis using SnpEff 16 (genetic 80 variant annotation and effect prediction toolbox) revealed that 65,333 (94%) of these variants 81
were single nucleotide polymorphisms (SNPs), 1,404 (2%) were insertions, and 2,582 (4%) 82 were deletions. As shown in Figure 1 , the majority of these occur within intronic regions 83 (~75%), with the remainder located 3' or downstream (~11%), 5' or upstream (~9%), and 84 exonic (~2%). Of the coding variants, approximately half of these variants are missense 85 (~49%), or synonymous mutations (~50%) with some occurrences of nonsense (~1%) 86 mutations. We compared our findings with annotation results of whole genome sequencing 87 data of 1000 Genome Project phase I dataset (http://snpeff.sourceforge.net/1kg.html) and 88 confirmed that the results of variant annotation within 160 PGx genes are within an expected 89 range (Supplemental figure 1) . 90
Linkage disequilibrium analysis 91
We assessed the LD between associated variants within known pharmacogenomics loci and 92 variants identified in our study. Analysis of LD was done in each of the four populations 93 (American, European, East Asian, African) from Phase I of 1000 Genomes Project. This resulted in 8,207 novel variants forming 21,256 instances of LD (r 2 > 0.8) with 859 known 95 pharmacogenomics variants (Supplemental data 3). 96
High-impact variations 97
We identified 8 variants predicted to have a high-impact using SNPEff from the 1000 GP 98 database that were in LD (r 2 > 0.8) with 22 known pharmacogenomics variants. These 99 included potentially functional variants that code for an alternative splice donor site, 100 structural interaction, frameshift mutation, stop gain, or stop lost variation. Table 1 lists these 101 new LD variants along with the corresponding pharmacogenomics variants, the majority of 102 which are predicted to be non-coding located within introns, up/downstream, and 103 synonymous, with only few instances of missense and frameshift variants). 104
Moderate-impact variations 105
We identified 19 missense variants that are in LD with 32 pharmacogenomics variants, which 106 are predicted to have a moderate, low, or modifying effects by SNPEff ( Table 2) . Among the 107 newly identified variants, two are regulatory variants that could potentially affect protein 108 binding, and one has been associated with neural tube defects and spina bifida cystica. 109
Low-impact variations 110
of RegulomeDB database, which are known eQTLs or variants correlated with variable gene 117 expression. Among 324 modifier variants with RegulomeDB scores, 84 variants were 118 classified as category 1, forming 213 instances of LD with 73 pharmacogenomics variants 119 which are predicted to have low or modifying effects (Supplemental data 4). 120
Variants associated with clinical outcomes 121
Using SNPedia database, we discovered 46 variants in LD that are correlated with clinical 122 phenotypes as documented in Supplemental data 5. 123
Discussion 124
This manuscript reports the identification of potentially functional genetic variants within 125 genes previously correlated with drug response outcomes. We show that some of the novel 126 variants identified from next-generation sequencing (NGS) of whole genomes (Phase I of the 127 1000 Genomes Project) are in LD with well-known pharmacogenomics variants and could 128 account for the functional basis underlying the association signals. Many of these LD variants 129 code for non-synonymous amino acid substitutions, frame-shift mutations, introduce a splice 130 variant that results in alternative splicing of the transcript, or located in non-coding regions 131 but are correlated with gene expression levels (expression quantitative trait loci or eQTL) or 132 other clinical phenotypes. 133
In this study, we used LD analysis to determine the correlation between novel genetic 134 variants identified from the 1000 Genomes Project database and known pharmacogenomics 135 variants. We reasoned that any variant(s) in strong LD (r 2 > 0.8) with the known 136 pharmacogenomics loci could account for the association signal and have potential to be the 137 actual causal variants at these genomic loci. In order to prioritize the identified variants, we used a popular annotation toolbox (SNPEff) to predict the function of each variant. In 139 addition, we used additional information such as RegulomeDB and SNPedia to prioritize the 140 variant(s) of higher impact from those with low impact. 141
Many of the variants we identified are "novel" in that these have not been reported in 142 earlier pharmacogenomics studies. For example, we identified a splice donor variant 143 (rs28364311) located on a VIP gene ADH1A. This variant is in LD with a pharmacogenomics 144 associated variant, rs6811453, which is associated with increased resistance to cytarabine, 145 fludarabine, gemtuzumab ozogamicin and idarubicin in patients with acute myeloid 146 leukemia. 17 The associated pharmacogenomics variant is non-coding and have no known 147 biological function as it is located downstream (3') of the gene. Considering the potential 148 impact of rs28364311 on splicing and its strong LD with the associated pharmacogenomics 149 variant, it is plausible that the splice variant identified is the functional variant that accounts 150 for the original association signals at this locus. 151
Moreover, we identified that a stop gain variant rs4330 from the VIP gene ACE, 152 encoding the angiotensin-converting enzyme, is in LD with 6 known pharmacogenomics 153 variants (rs4341, rs4344, rs4331, rs4359, rs4363, and rs4343). Whereas the latter are intronic 154 or code for synonymous changes, which are less likely to have detrimental effects on the gene 155 product, the identified rs4330 codes for a truncated protein that is likely to have detrimental 156
effects. 157
Another example is a modifier variant (rs2854509), which we report to be in LD with 158 a pharmacogenomics variant (rs3213239) that is associated with decreased overall survival 159 and progression-free survival when treated with Platinum compounds in patients with non-whereas pharmacogenomics variant rs3213239 is located upstream of gene encoding X-Ray 162
Repair Cross Complementing 1 protein (XRCC1). Our analysis revealed that variant 163 rs2854509 is a cis-eQTL variant acting on CPIC gene XRCC1, which is associated with 164 variable efficacy in in platinum-based chemotherapy agents. Additional findings from 165
RegulomeDB showed a direct evidence of binding-site alteration through ChIP-seq and 166
DNase with a matched position weight matrix to the ChIP-seq factor and a DNase footprint. 167
These findings suggest the possibility that rs2854509 has regulatory effects on the gene 168 XRCC1, which could modulate response to platinum based chemotherapy treatments. 169
Our proof of principle study demonstrates that many of the well-known 170 pharmacogenomics loci from PharmGKB are genetic markers that may tag causal variants. 171
Often the latter remain elusive and are likely to be in linkage disequilibrium (LD) with the 172 associated markers. Using NGS data, we identified a number of sequence variants in LD with 173 these pharmacogenomics loci with supporting functional evidence from current annotation 174 softwares. These findings, pending experimental evidence, will ultimately facilitate the 175 translation of improved clinical assays to predict response for a particular drug or dosage 176 prior to administration. The implementation of these clinical tests promises to improve 177 efficacy of drug therapy while reducing the incidence of adverse events. 18 178
One limitation of the approach taken is the exclusion of rare variants (minor allele 179 frequency < 0.01). While rare variants are more likely to be functional and clinically relevant, 180 our decision to exclude them from this study was based on the limited sample size (approx. 181 200-400 in each of the four main populations: American, European, East Asian, African) of 182 1KGP Phase 1. Specifically, we would not be able to determine LD among rare variants 183 (MAF < 0.01) in such small populations. Another limitation is that this study was based on bioinformatics methods and we did not experimentally validate the potentially functional 185 variants identified, nor confirm their correlation with drug response outcomes. Instead our 186 study was proof of concept that associated variants in well-established pharmacogenomics 187 genes could represent markers of drug response rather than the casual variants. Further 188 studies are needed to identify and ultimately validate the often elusive functional variants in 189 these loci. These additional studies include genotyping of these potentially functional variants 190 (identified in LD with the associated variants) and testing them directly for correlation with 191 drug response outcomes in clinical trials. Other experiments are needed to confirm the 192 biological impact of these variants on the resultant RNA transcripts or proteins, which 193 depends on the predicted impact of the variants identified. For example, variants of high 194 impact ( Table 1) Our study identified novel genetic variations located in well-established 198 pharmacogenomics genes, which could account for the association signals at these loci and 199 have strong impact on the resulting gene products. We applied an innovative approach that 200 combined bioinformatics resources such as PharmGKB, sequencing data from the 1000 GP, 201 population annotation software such as SNPEff as well as databases such as RegulomeDB to 202 identify novel variants and predict their functional effects within pharmacogenomics loci. 203
Moreover, we determined that a number of these potentially functional variants are in LD 204 with known pharmacogenomics variants and could account at least in part for the original 205 association signals. Identification of these elusive causal variants could facilitate more 206 accurate genetic tests to predict treatment response prior to drug administration. The improved accuracy results from direct testing instead of relying on LD, which varies among 208 populations (as noted by our study of LD across 4 populations in the 1000 GP). Thus, 209 identification of causal variants will improve the translation of pharmacogenomics findings 210 into clinical practice and ultimately replace the current trial and error approach for drug 211 therapy, moving us closer towards precision medicine. 212
Methods 214
Pharmacogenomic genes 215
We selected 160 unique pharmacogenomics associated loci, containing 127 CPIC genes (June 216 5 th , 2017 release) and 64 VIP genes (May 1st, 2017 release) from the PharmGKB database. 217
Then, we identified the genomic coordinates of each gene from the GRCh37/hg19 assembly 218 of the human reference genome using the University of Santa Cruz (UCSC) Genome 219
Browser. 19 Next, genomic coordinates were padded with 5000 bp both 5' and 3' of each gene 220 to include potential regulatory regions. All variants that appear in at least 1% of the 1000 221
Genomes Project Phase I population (Feb. 2009 release) were extracted. 222
Functional annotations 223
After reviewing many annotation tools (including annoVar, VEP, Polyphen/SIFT, CADD), we 224 decided that SnpEff best meets our needs as it allows a great degree of compatibility with 
Linkage disequilibrium (LD) between the well-established pharmacogenomics variants 236
(1,151 variants annotated by PharmGKB retrieved on June 16 th , 2017, that are found within 237 160 PGx loci and 1000 Genomes project phase 1 dataset) and identified variants from the 238 1000 Genomes Project phase 1 dataset using Plink (version 1.09). 20 Distance window for the 239 LD analysis were set to 1Mb and an r 2 threshold of > 0.8. 240
SNPs associated with regulation and phenotypes 241
For each variant identified to be in LD with an established pharmacogenomic variant, we 242 used RegulomeDB 21 to evaluate and score those that have the potential to cause regulatory 243 changes, such as eQTL, regions of DNAase hypersensitivity, binding sites of transcription 244 factors and proteins. RegulomeDB uses GEO 22 , the ENCODE 23 project, and various 245
published literatures to assess these information. In addition to that, we used SNPedia 24 , a 246 database of over 90,000 SNPs and associated peer-reviewed scientific publications, to 247 identify variants that are previously associated with phenotypes. (Figure 2 
Supplemental Figure 1. Comparison of annotation findings between variants from 160
PGx genes and whole genome. a) 94% of variants identified in 160 PGx genes were SNPs, 4% deletions, 2% insertions. These numbers are similar to the whole exome data from the 1000 GP. b) Annotation of coding regions within 160 PGx genes identified 49% missense, 50% silent, and 1% nonsense variations. Annotation results from the entire exome had a slightly higher rate of missense mutations and lower rate of silent mutations. However, the ratio of missense to silent mutations in the human exome is expected to be approx. 1.0. Thus, we concluded that our findings fall within the expected range. c) In both whole genome and the 160 PGx genes, the majority of variants fall within intronic regions. Whole genome annotations resulted in higher number of intergenic variants (~12%) compared 160 PGx genes (~1.5%). This is due to the fact that we had included limited (5000 bp) flanking regions in our targeted PGx genes in contrast to whole genome sequences. Other than intergenic regions, variants located 5', 3', exons, and splice sites occurred with similar frequencies in our candidate genes compared to the whole genome. Abbreviations: Chr = Chromosome, EUR r2 = linkage disequilibrium in the European Population of 1000 Genomes project measured in r-squared; EAS r2 = linkage disequilibrium in the Eastern Asian Population of 1000 Genomes project measured in r-squared; AMR r2= linkage disequilibrium in the American Population of 1000 Genomes project measured in r-squared; AFR r2 = linkage disequilibrium in the African Population of 1000 Genomes project measured in rsquared. Annotation definitions: structural interaction variant = These are "within protein" interaction loci, which are likely to be supporting the protein structure. They are calculated from single protein PDB entries, by selecting amino acids that are: a) atom within 3 Angstrom of each other; and b) are far away in the AA sequence (over 20 AA distance). The assumption is that, since they are very close in distance, they must be "interacting" and thus important for protein structure. For more information, see http://snpeff.sourceforge.net/SnpEff_manual.html. 
